Page 3«..2345..1020..»

Category : Human Longevity

CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

Link:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire

Recommendation and review posted by Alexandra Lee Anderson

Trending Now: Adrenomyeloneuropathy Treatment Market Brief Analysis and Application, Growth by 2026| Ascend Biopharmaceuticals, Novadip Biosciences,…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Adrenomyeloneuropathy Treatment Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Adrenomyeloneuropathy Treatment market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Adrenomyeloneuropathy Treatment market include: Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1664172/global-adrenomyeloneuropathy-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Adrenomyeloneuropathy Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Adrenomyeloneuropathy Treatment Market Segment By Type:

Steroid Replacement TherapyStem Cell Transplant By the end users, this report covers the following segmentsHospitalsClinicsAmbulatory Surgical CentersOthers Competitive Landscape: The Adrenomyeloneuropathy Treatment key manufacturers in this market include:Ascend BiopharmaceuticalsNovadip BiosciencesEureka TherapeuticsHuman LongevityRegeneusAllogene TherapeuticsBioRestorative TherapiesImmatics BiotechnologiesNewLink GeneticsCytori TherapeuticsTalaris Therapeutics

Global Adrenomyeloneuropathy Treatment Market Segment By Application:

HospitalsClinicsAmbulatory Surgical CentersOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Adrenomyeloneuropathy Treatment market.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1664172/global-adrenomyeloneuropathy-treatment-market

TOC

1 Market Overview of Adrenomyeloneuropathy Treatment1.1 Adrenomyeloneuropathy Treatment Market Overview1.1.1 Adrenomyeloneuropathy Treatment Product Scope1.1.2 Market Status and Outlook1.2 Global Adrenomyeloneuropathy Treatment Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Adrenomyeloneuropathy Treatment Market Size by Region (2015-2026)1.4 Global Adrenomyeloneuropathy Treatment Historic Market Size by Region (2015-2020)1.5 Global Adrenomyeloneuropathy Treatment Market Size Forecast by Region (2021-2026)1.6 Key Regions Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.1 North America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.2 Europe Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.3 China Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.5 Latin America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Adrenomyeloneuropathy Treatment Industry Impact1.7.1 How the Covid-19 is Affecting the Adrenomyeloneuropathy Treatment Industry

1.7.1.1 Adrenomyeloneuropathy Treatment Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Adrenomyeloneuropathy Treatment Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Adrenomyeloneuropathy Treatment Players to Combat Covid-19 Impact 2 Adrenomyeloneuropathy Treatment Market Overview by Therapy2.1 Global Adrenomyeloneuropathy Treatment Market Size by Therapy: 2015 VS 2020 VS 20262.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by Therapy (2015-2020)2.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Therapy (2021-2026)2.4 Steroid Replacement Therapy2.5 Stem Cell Transplant 3 Adrenomyeloneuropathy Treatment Market Overview by Therapy3.1 Global Adrenomyeloneuropathy Treatment Market Size by End Users: 2015 VS 2020 VS 20263.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by End Users (2015-2020)3.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by End Users (2021-2026)3.4 Hospitals3.5 Clinics3.6 Ambulatory Surgical Centers3.7 Others 4 Global Adrenomyeloneuropathy Treatment Competition Analysis by Players4.1 Global Adrenomyeloneuropathy Treatment Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenomyeloneuropathy Treatment as of 2019)4.3 Date of Key Manufacturers Enter into Adrenomyeloneuropathy Treatment Market4.4 Global Top Players Adrenomyeloneuropathy Treatment Headquarters and Area Served4.5 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service4.6 Competitive Status4.6.1 Adrenomyeloneuropathy Treatment Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Ascend Biopharmaceuticals5.1.1 Ascend Biopharmaceuticals Profile5.1.2 Ascend Biopharmaceuticals Main Business and Companys Total Revenue5.1.3 Ascend Biopharmaceuticals Products, Services and Solutions5.1.4 Ascend Biopharmaceuticals Revenue (US$ Million) (2015-2020)5.1.5 Ascend Biopharmaceuticals Recent Developments5.2 Novadip Biosciences5.2.1 Novadip Biosciences Profile5.2.2 Novadip Biosciences Main Business and Companys Total Revenue5.2.3 Novadip Biosciences Products, Services and Solutions5.2.4 Novadip Biosciences Revenue (US$ Million) (2015-2020)5.2.5 Novadip Biosciences Recent Developments5.3 Eureka Therapeutics5.5.1 Eureka Therapeutics Profile5.3.2 Eureka Therapeutics Main Business and Companys Total Revenue5.3.3 Eureka Therapeutics Products, Services and Solutions5.3.4 Eureka Therapeutics Revenue (US$ Million) (2015-2020)5.3.5 Human Longevity Recent Developments5.4 Human Longevity5.4.1 Human Longevity Profile5.4.2 Human Longevity Main Business and Companys Total Revenue5.4.3 Human Longevity Products, Services and Solutions5.4.4 Human Longevity Revenue (US$ Million) (2015-2020)5.4.5 Human Longevity Recent Developments5.5 Regeneus5.5.1 Regeneus Profile5.5.2 Regeneus Main Business and Companys Total Revenue5.5.3 Regeneus Products, Services and Solutions5.5.4 Regeneus Revenue (US$ Million) (2015-2020)5.5.5 Regeneus Recent Developments5.6 Allogene Therapeutics5.6.1 Allogene Therapeutics Profile5.6.2 Allogene Therapeutics Main Business and Companys Total Revenue5.6.3 Allogene Therapeutics Products, Services and Solutions5.6.4 Allogene Therapeutics Revenue (US$ Million) (2015-2020)5.6.5 Allogene Therapeutics Recent Developments5.7 BioRestorative Therapies5.7.1 BioRestorative Therapies Profile5.7.2 BioRestorative Therapies Main Business and Companys Total Revenue5.7.3 BioRestorative Therapies Products, Services and Solutions5.7.4 BioRestorative Therapies Revenue (US$ Million) (2015-2020)5.7.5 BioRestorative Therapies Recent Developments5.8 Immatics Biotechnologies5.8.1 Immatics Biotechnologies Profile5.8.2 Immatics Biotechnologies Main Business and Companys Total Revenue5.8.3 Immatics Biotechnologies Products, Services and Solutions5.8.4 Immatics Biotechnologies Revenue (US$ Million) (2015-2020)5.8.5 Immatics Biotechnologies Recent Developments5.9 NewLink Genetics5.9.1 NewLink Genetics Profile5.9.2 NewLink Genetics Main Business and Companys Total Revenue5.9.3 NewLink Genetics Products, Services and Solutions5.9.4 NewLink Genetics Revenue (US$ Million) (2015-2020)5.9.5 NewLink Genetics Recent Developments5.10 Cytori Therapeutics5.10.1 Cytori Therapeutics Profile5.10.2 Cytori Therapeutics Main Business and Companys Total Revenue5.10.3 Cytori Therapeutics Products, Services and Solutions5.10.4 Cytori Therapeutics Revenue (US$ Million) (2015-2020)5.10.5 Cytori Therapeutics Recent Developments5.11 Talaris Therapeutics5.11.1 Talaris Therapeutics Profile5.11.2 Talaris Therapeutics Main Business and Companys Total Revenue5.11.3 Talaris Therapeutics Products, Services and Solutions5.11.4 Talaris Therapeutics Revenue (US$ Million) (2015-2020)5.11.5 Talaris Therapeutics Recent Developments 6 North America Adrenomyeloneuropathy Treatment by Players and by End Users6.1 North America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)6.2 North America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 7 Europe Adrenomyeloneuropathy Treatment by Players and by End Users7.1 Europe Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)7.2 Europe Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 8 China Adrenomyeloneuropathy Treatment by Players and by End Users8.1 China Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)8.2 China Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 9 Rest of Asia Pacific Adrenomyeloneuropathy Treatment by Players and by End Users9.1 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 10 Latin America Adrenomyeloneuropathy Treatment by Players and by End Users10.1 Latin America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)10.2 Latin America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 11 Middle East & Africa Adrenomyeloneuropathy Treatment by Players and by End Users11.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 12 Adrenomyeloneuropathy Treatment Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Originally posted here:
Trending Now: Adrenomyeloneuropathy Treatment Market Brief Analysis and Application, Growth by 2026| Ascend Biopharmaceuticals, Novadip Biosciences,...

Recommendation and review posted by Alexandra Lee Anderson

A Movie of the Evolving Universe Is Potentially Scary – Scientific American

After the COVID-19 rules about social distancing went into effect, I developed a morning routine of jogging through the woods near my home. During the first months, I focused on the green branches that stretch upward towards the sky, but recently I started to notice the debris of tree trunks lying on the ground. There are many such remnants, eaten by termites, rotting and ultimately dispersing into the underlying soil. A glimpse at the forest reveals a sequence of evolutionary phases in the history of trees that lived or died at different times.

The phenomenon happens in other contexts. For example, I recently completed a nine-year term as chair of the Astronomy Department at Harvard. And only now have I begun to notice the former chairs scattered around me, just like those tree trunks in the woods.

Entering a new stage of life can be humbling. We acquire a false sense of permanence from reviewing the frozen past, as if it were a statue that will never erode. But this view is shortsighted, since each moment can also be seen a new beginning, shaped by forces beyond our control and swirling on a grander scale.

Old-fashioned astronomy was also permeated by a false sense of permanence. Astronomers collected still images of the universe, creating the impression that nothing really changes under the sunor above it, either. But just like the revelation from my stroll through the woods, these snapshots showed stars and galaxies of different ages, at various evolutionary phases along their history. Computer simulations helped us patch together the full story by solving the equations of motion for matter, starting from the initial conditions imprinted on the cosmic microwave background at early cosmic times. By generating snapshots of an artificial cosmos similar to those captured by telescopes, these simulations unraveled our cosmic roots. The scientific insight that emerged is that the likely origins for our existence were quantum fluctuations in the early universe. Perhaps we should add Quantum Mechanics Day to our annual celebrations of Mothers Day and Fathers Day.

There are some missing pages in the photo album made up of our observations, however: the period known as the cosmic dawn, for example, when the first stars and galaxies turned on. These missing pages will be filled in the coming decade by the next generation of telescopes, such as the James Webb Space Telescope (JWST), the ground-based "extremely large" telescopes and the Hydrogen Epoch of Reionization Array (HERA).

To reveal a more literal gap in the sky, the Event Horizon Telescope recently captured a still image of the silhouette of the black hole in the giant galaxy M87. The next goal is to obtain a sequence of images or a video, showing the time variability of the accretion flow around the black hole.

The tradition of still images makes sense when dealing with systems like galaxies, which evolve on a timescale of billions of years. But the universe also exhibits transient fireworks that flare up and dim during a human lifetime. Observing them is the motivation behind the Legacy Survey of Space and Time (LSST) on the Vera C. Rubin Observatory, which will have its first light soon. LSST will be a filming project, documenting nearly a thousand deep multicolor images per patch of the southern sky over a decade and recording the most extensive video of the universe ever taken with its plethora of transients in full glory.

Some of the LSST flares are expected to be the counterparts of gravitational wave sources detected by LIGO/Virgo or LISA. Their discovery will usher in multi-messenger astronomy based on both gravitational and electromagnetic waves emitted by the same sources, providing new insights about the central engines that power these transients. The related standard sirens could serve as new rulers for measuring precise distances in cosmology.

Within the Milky Way, transient events close to Earth could lead to catastrophe. A supernova explosion, for example, could cause a mass extinction on an unprecedented scale. If a meteor similar to the one that hit the unpopulated regions near Chelyabinsk in 2013 or Tunguska in 1908 hit New York City, it could cause a far larger death toll and economic damage than COVID-19. Or consider the impact of a blob of hot gas from the Sun, a so-called coronal mass ejection of the type that missed the Earth in 2012. Such an event could shut off communication systems, disable satellites and damage power grids. Altogether, astronomical alerts about such celestial threats could be crucial for securing the longevity of our species.

Of greatest relevance for our long-term survival is identifying large objects on a collision course with the Earth, similar to the Chicxulub asteroid that killed the dinosaurs 66 million years ago. In 2005, Congress passed a bill requiring NASA to find and track at least 90 percent of all near-Earth objects larger than 140 meters (enough to cause regional devastation) by 2020. Only a third of these objects have been identified in the sky so far. In a recent paper with my undergraduate student Amir Siraj, we explained some puzzling properties of the Chicxulub asteroid as a tidal breakup of a long-period comet that passed close to the sun. If future sky surveys alert us to another fragment whose apparent size grows rapidly against the sky, wed better have a contingency plan to deflect its trajectoryor else immediately call our realtor.

Keeping up with the challenge of precision cosmology for the next few decades can demonstrate that the Hubble constant, which describes the expansion rate of the universe, is not really a constant, in accordance with the expected Sandage-Loeb test. In the long run, the only thing that stays constant is change. The accelerated expansion of the universe under the influence of so-called dark energy will be the ultimate manifestation of extragalactic social distancing in the post-COVID-19 era, preventing any future contact between us and civilizations outside our galaxy.

View post:
A Movie of the Evolving Universe Is Potentially Scary - Scientific American

Recommendation and review posted by Alexandra Lee Anderson

L.A. Zoo’s lion soulmates euthanized together after age-related health problems – CTV News

Hubert and Kalisa were best friends for life.

The African lion duo spent many years together, never having cubs with each other but companions, nonetheless.

But on Thursday, their partnership came to an end. The Los Angeles Zoo made the decision to humanely euthanize the two lions, due to declining health and age-related illnesses.

"Hubert and Kalisa are an iconic part of the L.A. Zoo experience, and our staff and guests have been touched by their loyal companionship," Denise Verret, director of the L.A. Zoo, said in a statement. "Their longevity is truly a testament to the level of expert care our veterinary and animal care teams provide for our elderly animals. These lions will remain a positive part of our history, and they will be greatly missed."

Hubert, born Feb. 7, 1999, and Kalisa, born Dec. 26, 1998 spent six years together at the L.A. Zoo, and even more while at the Woodland Park Zoo in Seattle.

The average life expectancy for African lions in the wild is mid-teens, whereas in captivity is about 17 years, the L.A. Zoo said.

Their population in the wild is estimated between 23,000 to 39,000, but declining, the L.A. Zoo said. The IUCN Red List of Threatened Species lists the animals as "vulnerable" because of "human-wildlife conflict, prey depletion, the illegal trade of lion body parts for traditional medicine, trophy hunting, and disease," the zoo said.

See the article here:
L.A. Zoo's lion soulmates euthanized together after age-related health problems - CTV News

Recommendation and review posted by Alexandra Lee Anderson

Mesenchymal Stem Cells Market With Top 20 Countries data Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026…

Coherent Market Insights announced that its published an exclusive report namely Global Mesenchymal Stem Cells Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Mesenchymal Stem Cells Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

Get PDF Brochure Of This Report Here @ https://www.coherentmarketinsights.com/insight/request-pdf/720

The report presents an overview of Mesenchymal Stem Cells Market consist of objectives study and definition of Mesenchymal Stem Cells. The next section focuses on market size, region-wise Mesenchymal Stem Cells growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Mesenchymal Stem Cells Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

Following market aspects are enfolded in Global Mesenchymal Stem Cells Market Report:

A wide summarization of the Global Mesenchymal Stem Cells Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Mesenchymal Stem Cells Market. Analysis of company profiles of Top major players functioning in the market.

Mesenchymal Stem Cells Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Mesenchymal Stem Cells Market players in detail. Mesenchymal Stem Cells Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Key questions answered in Report:-

Mesenchymal Stem Cells Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Mesenchymal Stem Cells, Guidelines Overview and Upcoming Trends Forecast till 2027 Mesenchymal Stem Cells Market Top Companies Sales, Price, Revenue and Market Share Outlook Mesenchymal Stem Cells Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Mesenchymal Stem Cells by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Mesenchymal Stem Cells Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

****Stay Home. Stay Safe****

Read more here:
Mesenchymal Stem Cells Market With Top 20 Countries data Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026...

Recommendation and review posted by Alexandra Lee Anderson

Why The Founder Of TOMS Shoes Wants You To Learn Ten New Habits – Forbes

Blake Mycoskie, co-founder of Madefor

The story of Blake Mycoskie starting TOMS Shoes is well known in entrepreneurial circles.While many would be content after building a half billion-dollar business, Blake is not one of them.After experiencing his own burnout after TOMS, Blake was inspired to start Madefor, a 10-month program where people learn a new habit or practice each month.We sat down to talk about the inspiration for Madefor and why this focus on well-being is more important than ever.

Dave Knox:With Madefor, you are in the middle of building your second business.What is the biggest lesson you took away from building TOMS that you are applying to Madefor?

Blake Mycoskie: I think the biggest thing that I took away is really when you're focused on building a business that has a big mission and specifically one that can serve so many people, it's really easy to build incredible culture in your company and attract amazing talent as a result. At first, when I was trying to put together this kind of dream team of scientists on human behavior, I thought it was going to be really challenging to do because they are very busy and get a lot of requests for their time and attention. But when we told them that our mission was to eliminate some of the suffering that comes from modern living, and use the science that they have studied in their lab to help people sleep better, and eat better, and feel better, and be more connected and more grateful, every single one of them just signed on immediately. So many of these scientists dedicated their lives to something very specific.How do you optimize the perfect night's sleep.How do you really declutter your life, both in your work life and in your personal life, in a way that frees your mind up to be more creative? Giving them the opportunity to get that science out of their labs and into the hands of people in a way that they can not only learn these habits, but more importantly, sustain them, everyone jumped on. I think I learned that because that was the same case with TOMS, when we said," We're going to sell shoes so that we can give shoes to children in need," we had some of the top talent in the country join the company. I think having a big mission and especially one that hits home is an incredible way to build the necessary talent for a new startup.

Knox:Building a company is a roller coaster. What was the impetus that had you want to jump back on and build a second venture?

Mycoskie:After spending over a decade building TOMS to a half a billion- dollar business and giving 96 million children's shoes, I felt pretty dang content with the entrepreneur business aspect of my life. I wasn't really thinking that I was going to jump back into a startup or a business, at least until my kids went to college. But what happened was is I had a deeply profound, personal experience that radically changed my life, and my mental health, and my wellbeing, and my physical health, and so much so that my only response out of the gratitude from my experience was to share this with as many people as possible. In doing that, I developed this Madefor program, which is a 10- month program where people learn a new habit and practice, one a month for 10 months. And they are the exact habits and practices I learned from some of the top scientists in the world. I just felt like I had to share it, and that turned into a new business.

Knox:How did you go about finding those experts and the habits that inspired Madefor in the first place?

Mycoskie:I was on this journey to really learn from the best minds in science, around how people would really live their best life, who's really flourishing and why, and most particularly why I wasn't feeling that way. I had all the kind of markers of success, an incredible business, helped millions of kids around the world, a great family and friends. But in 2017, I found myself quite burned out and actually diagnosed with mild depression. As I looked deep into it, what I recognized was there were a lot of these basic things from a physical and mental and even purposeful level that I kind of put on the back burner when I was charging and working so hard in building TOMS. And at that same time, I met a gentleman who ultimately became my business partner, named Pat Dossett, and he was a Navy Seal for nine years and had a very specific focus on after his time on the teams of really human potential and flourishing. When I talked to him about some of my own struggles, he and I together, agreed to reach out to the scientific community. The first person we reached out to was a neuroscientist at Stanford named Andrew Huberman who really opened our eyes to this idea of a fixed mindset versus growth mindset, and how the neuroplasticity in your brain can allow you to learn and sustain new habits that will make a huge difference in your life, no matter how old you are. The other thing that Andrew really helped us do is identify the other top scientists studying really critical habits like human connection, gratitude, breath work, sleep, all around the country. We just went on this one-year-long research and experimentation phase where we not only tested these practices on ourselves, but really learned from these scientists. Ultimately, after doing extensive research for over a year, we found that there weren't 12 things, there were only 10. So the Madefor program is only 10 months. And with those 10 things, we spend a lot of time testing on ourselves and with beta groups to really understand what is the proper order. And the order is really set to coincide with neuroplasticity and how you can not only learn but sustain these habits. Some people would say they sequentially get harder. I actually think that you are just priming your brain so that you can take on different ones in the order that they go. But ultimately, they end with helping all of our members answer this question that I believe all of us answer or want to answer at some point in our life, and that is what am I made for? And that's where the name Madefor comes from.

Knox:One of the most fascinating parts of the program is the fact that while everything in the world is going digital, you guys chose to go analog. What drove that choice?

Mycoskie:The answer is science. My business partner, Pat Dossett, is the most non- bullshit guy you'll ever meat. He is just allergic to anything that feels like a fad, or a trend, or anything like that. While there are huge trends in using digital devices to tell us our heart rates and our sleep and all of these things, what the science showed was it is extremely difficult to learn and sustain a new habit if you're constantly digitally distracted. We decided to make our program completely analog by sending you a kit once a month. And in that kit, you are going to learn one basic thing. Now, these are not crazy, bio-hacking, out-there stuff. This is stuff like, how can you absolutely know that you're doing everything possible, in a very simple way, to optimize and get the perfect amount of sleep? The right amount of deep sleep and the right amount REM sleep where you are looking at how do you wake up feeling more refreshed than you've ever felt in your life? And why, scientifically is that so important for your longevity and your mental clarity, and your mood? The thing is, is we decided that it was going to be more expensive, and it was going to take more time, but ultimately we're all about effectiveness. And the most effective way to help someone learn a new habit or practice and sustain it is to eliminate the digital distraction from the program. Once you sign up, there's very little digital interaction beyond that, and everything that you need comes in the box each month. In that box, we have the curated science. We take literally decades of science and curate it to about a 25 minute read that has been written by an incredible writer, who really can distill complex science into a very easy to understand concepts. The second thing is either one or two tools that Madefor has designed specifically for helping you adopt and learn that habit. And then the third thing in the box is your challenge card and your accountability measures so that you can really stay on-track during the month, as you learn that new habit and practice.

Knox:As you launched the business, what do you find is the spark for somebody signing up for Madefor?

Mycoskie:I think at some point, just like my own journey, is you need some form of a pain point. I don't think it necessarily needs to be a huge pain point like I was experiencing, mild depression and burnout, but it kind of is one of those things where you wake up one day and you're like," You know what? I really just don't sleep as well as I did when I was in my twenties, and it's getting worse as I get older. I don't really know what to do about it." Or," I always am dependent on that double espresso shot in the afternoon to give me energy and something innately just doesn't feel right on that. I feel like I'm running my adrenals and that's going to catch up with me." Or," I've been working so hard as an entrepreneur, or a CEO, or an executive that I've really lost touch with some of my closest friends. I really want to understand how that human connection and what are some very simple but effective ways that don't take a lot of time, but maybe will help me feel more connected, and that might help me feel better in my life?" It's all these little things that lead. It's usually not a big thing. We're trying to get to people early. The thing is, if we can help people develop these strong baselines that will really make them feel great and help them mentally and physically, and connect them more, and help them sleep better, and help their bodies move better, and get rid of those aches and pains, if we can do that, then they're less likely to go down this path of having what I would call a real mental health crisis.

Knox:With TOMS and now Madefor, your focus is on sparking positive change.What advice do you give to people on their companies authentically making a difference and not having it come off like a marketing play?

Mycoskie:I think so many companies and CEOs get this totally wrong, to be honest. You already kind of answered the question by using the word authentic. That word gets thrown around a lot, so I am sometimes hesitant to use it, but truly I haven't found a better word that better describes how a company can integrate a cause or a mission into their business. It has to be authentic. Usually, the way it is most authentic is if it comes from a personal experience that the CEO or the founder had. So obviously TOMS, I saw many children who were suffering from not having shoes in South America, and that personal story is what led to the initial growth of TOMS, and so many people connecting to the brand and the one- for- one movement. Now, my experience with having some burnout and dealing with the challenges of modern living and looking to science to help me feel better, is how we can authentically share that our mission is taken from a personal experience that wants to be shared with the world. And so that's the exact same type of situation. I really think that it's so critical that there's that personal story, that personal connection, from the leader of the organization, if you're going to integrate a cause or a mission into your business.

See the original post:
Why The Founder Of TOMS Shoes Wants You To Learn Ten New Habits - Forbes

Recommendation and review posted by Alexandra Lee Anderson

Janai: The story of ‘the sacred thread’ of some Hindu men – Online Khabar (English)

Almost all Hindus across Nepal celebrate the Janai Purnima festival on the full moon day of Shrawan every year, yet many of them do not know the essence of janai, the sacred thread that gave the festival its name.

So, here we have a detail of what a janai is and why it is important in the Hindu culture.

What is a janai?

Janai, often translated as a sacred thread, is a thread that has a high religious and cultural significance among the Hindu boys and men.

According to religious texts and people who have studied it, men from Bhramin, Kshetriya and Vaishya varna (hierarchical group) receive the honour of wearing a janai during a ritual called Bratabandha (Upanayana).

Rishi Ram Pokharel, a noted Sanskrit literature scholar of the country, says this thread is normally worn diagonally, from the left shoulder to right waist, crossing the chest. In Sanskirt, a janai is called Yagyopabita. Professor Pokharel explains, Yagya refers to any kind of worship, offering, devotion, or oblation. And, Upabita means something that has to be worn while performing yagyas. Such a thread that is made holy by chanting Vedic mantras. It is believed that these mantras established several Hindu gods and goddesses in the threads.

As per Pokharel, in the Satya Yug and Treta Yug, the janai used to be of gold and during the Dwapar Yug, it used to be of silver. Coming to the final Kali Yug, it is now made up of cotton. The thread for a Brahmin consists of six thinner strands whereas, for Kshetriyas, it is three. However, some add three additional strands as a substitute to the uttariya, an upper garment, that is considered mandatory for Hindu men while performing any yagyas.

Why is it worn?

It is believed that after adorning a janai, all the gods and goddesses enter and stay in their body, mind, and soul and make their life holy and meaningful.

As the janai is given to them during the Bratabandha, it constantly reminds the wearer that they are bounded by some vows and rules, making sure that they always follow their conduct and lessons taught by their gurus.

It is also believed that this thread grants knowledge, power, prosperity, and wisdom to the bearer. Hence, whoever adorns a janai, he is always expected to be dutiful, loyal, respectful, and truthful and be in discipline.

Not only this, but it is also said the janai grants the motivation to the wearer for performing good deeds and to be in pure character. Wearing a janai is believed to grant longevity and conspicuousness. Likewise, it is also believed that adoring the janai will protect the holder against negative thoughts and energy throughout his life.

Pokharel explains whereas a janai has three, six or nine strands (as described above), a strand has three smallest units, lets say fibres. Therefore, a basic unit of the janai has nine fibres. In every fibre, there lie all Hindu deities. Omkar that symbolises all the god and goddesses and the divine power in the first, Agni (the Fire God) in the second, Naag (the Serpent God) also considered the preserver of water resources in the third, Soma (the Moon) considered as of flora in the fourth, Pitri (forefathers) who are the guides and protectors in the fifth, Prajapati refering to the creator of the world in the sixth, Vayu or Maruta (the Air God) in the seventh, Surya (the Sun) in the eighth, and Vishwadev in the ninth fibre, Pokharel says, Therefore, there is a religious belief that these gods and goddesses living in the purified janai bestow the wearer the power and strength that lies within the gods.

Also, each of the three fibres is threefold and made one strand that counts the total of three strands, symbolising the holy Trimurti or three supreme gods: Brahma (the creator), Vishnu (the preserver) and Maheshwor (the destroyer). Some even consider these three strands are symbolic of body, speech, and mind, and believe the one who adorns this holy thread gains complete control over their body, speech, and mind.

It is not only the Janai Purnima when the wearers change their janai. In the Hindu scriptures, it is mentioned that the janai should be changed in the interval of four months, before doing any yagya, or after the completion of an impure period caused by birth or death in the close family.

In the scared Smriti (Puranas), Brahma is credited for the creation of this thread; that is why it got its another name, called Brahmasutra, according to Pokharel.

Exclusive to high-caste men?

Though the practice of wearing a janai is limited to Brahmins, Kshetriyas, and Vaishyas today, an expert on religion and culture, Basudev Krishna Shastri, briefs, Everyone, including all the men and women, has the right to this. Only after adorning the janai, one is considered eligible to perform all 16 rites of human life (sanskars).

He claims all people including men and women of all castes had the tradition of wearing a janai in the past. To justify, Shastri explains, Till date, while performing any yagyas or pujas be it Durga Puja or Swasthani Puja or Laxmi Puja, we (Hindu) offer yagyopabita (janai) to the goddesses as well. Symbolically offering a janai to the female deities during a yagya connotes that they adorn the janai.

Narrating one of the sections of a Hindi book, Vedic Vangmay mein Nari (meaning Women in Vedic Literature) by Dr Sushma Shukla, Shastri briefs, In the Sutra Sahitya (Sutra Literature), Griha Sutra (text that includes information regarding Vedic domestic rituals) and in other scriptures as well, it is mentioned that a wife should wear a janai while performing any yagyas. Also, it reads those women who adorn a yagyopabita are reverent and beautiful. For him, potey that modern women wear is also a symbol of the janai.

Later, this practice faded away coming to todays world as people found it very tough to be in a strict discipline that one has to follow after wearing a janai, Shastri claims.

Gradually, people nowadays even Brahmin and Kshetriya men stopped adorning the janai as one is bounded by vow and rules after wearing it and people find it very difficult and impractical to do so.

Published on August 3rd, Monday, 2020 9:06 AM

Download Onlinekhabar App. Android click here & IOS click here . Keep in touch with us on Facebook, Twitter & YouTube.

See the rest here:
Janai: The story of 'the sacred thread' of some Hindu men - Online Khabar (English)

Recommendation and review posted by Alexandra Lee Anderson

A Movie of the Evolving Universe, Potentially Scary – Scientific American

After the COVID-19 rules about social distancing went into effect, I developed a morning routine of jogging through the woods near my home. During the first months, I focused on the green branches that stretch upward towards the sky, but recently I started to notice the debris of tree trunks lying on the ground. There are many such remnants, eaten by termites, rotting and ultimately dispersing into the underlying soil. A glimpse at the forest reveals a sequence of evolutionary phases in the history of trees that lived or died at different times.

The phenomenon happens in other contexts. For example, I recently completed a nine-year term as chair of the Astronomy Department at Harvard. And only now have I begun to notice the former chairs scattered around me, just like those tree trunks in the woods.

Entering a new stage of life can be humbling. We acquire a false sense of permanence from reviewing the frozen past, as if it were a statue that will never erode. But this view is shortsighted, since each moment can also be seen a new beginning, shaped by forces beyond our control and swirling on a grander scale.

Old-fashioned astronomy was also permeated by a false sense of permanence. Astronomers collected still images of the universe, creating the impression that nothing really changes under the sunor above it, either. But just like the revelation from my stroll through the woods, these snapshots showed stars and galaxies of different ages, at various evolutionary phases along their history. Computer simulations helped us patch together the full story by solving the equations of motion for matter, starting from the initial conditions imprinted on the cosmic microwave background at early cosmic times. By generating snapshots of an artificial cosmos similar to those captured by telescopes, these simulations unraveled our cosmic roots. The scientific insight that emerged is that the likely origins for our existence were quantum fluctuations in the early universe. Perhaps we should add Quantum Mechanics Day to our annual celebrations of Mothers Day and Fathers Day.

There are some missing pages in the photo album made up of our observations, however: the period known as the cosmic dawn, for example, when the first stars and galaxies turned on. These missing pages will be filled in the coming decade by the next generation of telescopes, such as the James Webb Space Telescope (JWST), the ground-based "extremely large" telescopes and the Hydrogen Epoch of Reionization Array (HERA).

To reveal a more literal gap in the sky, the Event Horizon Telescope recently captured a still image of the silhouette of the black hole in the giant galaxy M87. The next goal is to obtain a sequence of images or a video, showing the time variability of the accretion flow around the black hole.

The tradition of still images makes sense when dealing with systems like galaxies, which evolve on a timescale of billions of years. But the universe also exhibits transient fireworks that flare up and dim during a human lifetime. Observing them is the motivation behind the Legacy Survey of Space and Time (LSST) on the Vera C. Rubin Observatory, which will have its first light soon. LSST will be a filming project, documenting nearly a thousand deep multicolor images per patch of the southern sky over a decade and recording the most extensive video of the universe ever taken with its plethora of transients in full glory.

Some of the LSST flares are expected to be the counterparts of gravitational wave sources detected by LIGO/Virgo or LISA. Their discovery will usher in multi-messenger astronomy based on both gravitational and electromagnetic waves emitted by the same sources, providing new insights about the central engines that power these transients. The related standard sirens could serve as new rulers for measuring precise distances in cosmology.

Within the Milky Way, transient events close to Earth could lead to catastrophe. A supernova explosion, for example, could cause a mass extinction on an unprecedented scale. If a meteor similar to the one that hit the unpopulated regions near Chelyabinsk in 2013 or Tunguska in 1908 hit New York City, it could cause a far larger death toll and economic damage than COVID-19. Or consider the impact of a blob of hot gas from the Sun, a so-called coronal mass ejection of the type that missed the Earth in 2012. Such an event could shut off communication systems, disable satellites and damage power grids. Altogether, astronomical alerts about such celestial threats could be crucial for securing the longevity of our species.

Of greatest relevance for our long-term survival is identifying large objects on a collision course with the Earth, similar to the Chicxulub asteroid that killed the dinosaurs 66 million years ago. In 2005, Congress passed a bill requiring NASA to find and track at least 90 percent of all near-Earth objects larger than 140 meters (enough to cause regional devastation) by 2020. Only a third of these objects have been identified in the sky so far. In a recent paper with my undergraduate student Amir Siraj, we explained some puzzling properties of the Chicxulub asteroid as a tidal breakup of a long-period comet that passed close to the sun. If future sky surveys alert us to another fragment whose apparent size grows rapidly against the sky, wed better have a contingency plan to deflect its trajectoryor else immediately call our realtor.

Keeping up with the challenge of precision cosmology for the next few decades can demonstrate that the Hubble constant, which describes the expansion rate of the universe, is not really a constant, in accordance with the expected Sandage-Loeb test. In the long run, the only thing that stays constant is change. The accelerated expansion of the universe under the influence of so-called dark energy will be the ultimate manifestation of extragalactic social distancing in the post-COVID-19 era, preventing any future contact between us and civilizations outside our galaxy.

See the original post here:
A Movie of the Evolving Universe, Potentially Scary - Scientific American

Recommendation and review posted by Alexandra Lee Anderson

mTOR and the Science of Aging and Chronic Disease – The Doctor Weighs In

What if you could age slower and maintain your ability to be active and enjoy your family well into your 70s or 80s or beyond? What if you could delay the onset of chronic disease by almost a decade? Well, that is no longer a dream. Thanks to advances in the science of aging and chronic disease, we know that there are things that you can do now to impact your health and, perhaps, your longevity.

Lets start our discussion by diving into some of the basic science related to prolongation of a healthy lifespan. Dont worry, we are going to start with a video and its going to be fun.

First, check out this very entertaining short TED talk by Cynthia Kenyon who is a top scientist at the University of California at San Francisco Medical School. Then come back to this post for an expanded discussion.

The importance of Dr. Kenyons work and that of contemporary aging researchers is that they showed, for the first time, that aging and age-related chronic diseases arent things that just happen to us. [1] They are, in fact, related to an evolutionarily-conserved complex, highly regulated, and interconnected series of biochemical pathways.

Central to these pathways is a molecule called mTOR which stands for mechanistic Target of Rapamycin. It is so-named because rapamycin, a naturally occurring substance, inhibits the many of the activities of mTOR triggering a variety of metabolic and clinical outcomes. The most well-known of which is the extension of healthy lifespan.[2, 3]

mTOR exists as a complex of proteins called mTOR complex or mTORC. There are actually two different forms mTORC known as mTORC1 and mTORC2. Activation of the complexes occurs via different pathways. Once activated the mTOR complexes, in turn, activate or inhibit pathways critical to cell function. [2, 3]

mTORC1 and 2 are activated or inactivated depending on the availability of nutrients in the cells environment (e.g., glucose, amino acids and various growth factors). In fact, you can think of mTORC as integrating and responding to the energy status of the cells environment.

When times are good and energy, oxygen, nutrients, and growth factors is plentiful, mTORC1 is activated and stimulates metabolic pathways that lead to growth. When times are tough, those pathways are suppressed and the pathways related to survival are activated.

Here are some of the cellular functions mTORC1 regulates [2,4]:

The last two functions are inhibited when energy, nutrients, and growth factors are plentiful.

mTORC2 is activated by insulin and growth factors. [2,4] It regulates the following:

Rapamycin inhibits most but not all of the activities of mTORC1. However, it does not inhibit mTORC2 in the short run. There is some evidence that chronic administration of rapamycin, however, can inhibit mTORC2.[4] Further, there are important feedback pathways between mTORC1 and mTORC2.

Living organisms on our planet are subject to varying availability of nutrients and other sources of energy. In order to survive, they must be able to sample the energy availability in their surroundings and adjust accordingly.

mTOR-linked pathways provide that mechanism. Receptors found in cell membranes have both an external-facing component and an internal-facing component. The external component binds to nutrients, such as glucose, amino acids, oxygen, and various growth factors. As described above, this leads to the activation or inactivation of different intermediate proteins that ultimately activate or inhibit mTOR.

For example, during times of energetic stress, a protein known as AMPK is activated. This in turn inhibits mTORC1 and leads to activation or inhibition of other intermediate compounds. The result is a state of cellular activity that favors prolongation of lifespan.[5]

Although the pathways are incompletely understood, it is of note that dietary restriction a self-induced famine in a way is also associated with longevity.[5] We must remember, though, because of complex feedback loops, the ability to prolong lifespan via these mechanisms is not limitless.

On the other hand, during times of plenty, the availability of glucose increases. In addition to reducing the activation of AMPK, it also triggers the release of the hormone insulin and insulin-like growth factor). This leads to mTOR activation and creation of a state that favors growth and development including such things as elevated lipid levels that favor the development of chronic diseases.

Understanding the molecular biology of the mTOR pathways has some very practical applications. For example, as we have already pointed out, restricting calories is associated with reduced levels of some factors that inhibit mTORC1 and is associated with lifespan extension.[5] Intermittent fastingand exercise also reduce mTOR activity.

Also, restricting carbohydrates in people with Type 2 diabetes is known to lower blood glucose, insulin, and IGF-1 levels. The benefits of this type of diet does not require weight loss, although many do lose weight with carbohydrate restriction. [6] In fact, some experts have called for dietary carbohydrate restriction to be the first intervention prescribed in diabetes management. [6]

The prevailing American high-carbohydrate, high-fat fast-food diet, on the other hand, drives extra calorie intake and as well as higher levels of the factors that activate mTORC1. This, unfortunately, leads to metabolic conditions that accelerate the development of chronic diseases such as diabetes and heart artery problems.[6]

Metformin is the most commonly prescribed drug for Type 2 diabetes. It interferes with the same signaling pathways that we have been discussing. Specifically, it leads to the reduction of glucose, IGF-1, insulin levels. This, in turn, leads to inhibition of mTORC1. This results in a metabolic state that favors important health outcomes, such as:

Further, the drug has been proven to be safe with relatively few serious side effects. And, it is cheap, making it accessible even for people without health insurance.

Metformin is the also first drug approved by the FDA to enter a clinical trial to assess its effect on prolongation of a healthy lifespan. According to American Association for Aging Research, the Targeting Aging with Metformin (TAME) trials are a series of nationwide, six-year clinical trials at 14 leading research institutions across the country that will engage over 3,000 individuals between the ages of 65-79.

These trials will test whether those taking metformin experience delayed development or progression of age-related chronic diseasessuch as heart disease, cancer, and dementia.

As mentioned, the drug rapamycin inhibits mTORC1 activity and is associated with a prolonged lifespan. However, systemic rapamycin has unacceptable side effects, so its use is limited in humans.

It is used, however, for local applications. One example is the use of Sirolimus (the brand name of rapamycin) in early versions of drug-eluting stents (DES) used to treat coronary artery disease. [7]

More recently, scientists have modified rapamycin to create less toxic forms of the drug. They are known as rapalogs. These include everolimus, zotarolimus, and biolimus. Together with improved stent platform materials, the use of these DESs have been shown to lower thrombotic events related to the stents. [8]

There are a number of drugs that are used for cardiovascular disease that specifically impact the mTORC pathways by various mechanisms. For example, lisinopril (ACE inhibitor), losartan (angiotensin receptor blocker), atorvastatin (statin), and eplerenone (mineralocorticoid receptor blocker) all reduce oxidative particle formation. Indirectly, this lead to the inhibition of mTORC.

This, as we know, leads to metabolic changes that favor healthy aging. These effects on the mTOR-related signaling pathways may be the reason why these medications lower the risk of heart attack and stroke more than they reduce the target risk factors of blood pressure, lipid, and glucose levels.

On the other hand, tobacco smoke increases oxidative stress and favors the activation of mTORC pathways. This may eventually lead to Chronic Obstructive Lung Disease (COPD) and lung cancer.

Interfering with this core signaling is a form of precision medicine that impacts the molecular biology that causes cardiovascular disease, cancer, and accelerated aging. These medications are antioxidants that work.

Here is the most shocking insight. The same core signaling that causes accelerated aging, chronic disease, and ultimately death is essential to produce a perfectly developed newborn. At the moment of conception, there is a single cell that will ultimately become all the cells in the body with their vastly different functions.

The DNA for every cell in your body is the same. Epigenetic regulation determines which genes are turned on or off in a particular cell type. For example, normal EGFR function is necessary to establish pregnancy successfully at the very beginning of life. However, it contributes to chronic disease development later.

Angiotensin II is required to form a normal fetal kidney, but inappropriate activation later in life contributes to developing hypertension, chronic kidney disease, and congestive heart failure.

mTOR activation via nutrient sensing and growth factor signaling in the fetus directs a master symphony of switching genes on in just the right place, at just the right time, with just the right intensity for an exact amount of time to produce a perfect infant.

However, the same genes that are essential to coordinate normal development cause disease and death with chaotic activation later.

The human genome project did not give us the answers for accelerated aging and common chronic diseases. These problems are caused by normal genes that are inappropriately switched on later in life by things like aging, unhealthy diets, and tobacco smoke.

Specific highly effective generic medications with few side effects can block the signaling from those genes and lead to dramatically better clinical outcomes at a lower cost. Caloric restriction, intermittent fasting, exercise, and the specific medications mentioned all impact the same signaling.

New science, new systems, and new payment models can improve our health at a lower cost. All the necessary elements are available. It is time to bring the stakeholders together and get started.

2. Papadopoli D, Boulay K, Kazak L, et al. mTOR as a central regulator of lifespan and aging [version 1; peer-review: 3 approved] latest versions as of 07/27/20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611156/pdf/f1000research-8-18802.pdf

3. Weichhart T. mTOR as regulator of lifespan, aging and cellular senescence. Gerontology. (2018) 64(2):127-134.

4. Samidurai A, Kukreja R, Das A. Emerging role of mTOR signaling-related miRNAs in cardiovascular diseases. Oxidative Medicine and Cellular Longevity. Volume 2018, Article II6141902, 23 pages https//:doi.org/10.1155/2018/6141902.

5. Longo V, Antebi A, Bartke A, et al. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell (2015) 14, 497-510.

6. Feinman R, Pogozelski W, Astrup, A, et al. Dietary carbohydrate restriction as the f first approach in diabetes management: Critical review and evidence base. Nutrition(2015) 31:1-13.

7. Serruys P, Regar E, Carter A. Rapamycin eluting stent: the onset of a new era in interventional cardiology.Heart(2002) 87:305-305.

8. Im E, Hong, M-K. Drug-eluting stents to prevent stent thrombosis and restenosis (2016) 14(1):87-104

Healthy Life Extended by Eight Years in a Landmark Study

Heart Attacks: When Will We Finally Do What Needs to Be Done

Is There Really a Way to Reverse Diabetes?

A Unifying Hypothesis of Chronic Disease and Aging

Erectile Dysfunction: Is It a Sign of Heart Disease?

Why We Need to Unlock the Full Potential of Primary Care

Reshaping Healthcare: What We Can Learn From Alaska

Here is the original post:
mTOR and the Science of Aging and Chronic Disease - The Doctor Weighs In

Recommendation and review posted by Alexandra Lee Anderson

HABRI Advocates the Human-Animal Bond – Pet Age

No matter where you are, the four words in these uncertain times seem to precede every commercial, every newscast and every other piece of media across the globe. True enough, in this brave new world of COVID-19, anxiety and fear seem to be the marching orders of the day. Finding ways to safely destress and maintain mental health becomes a major priority when all the world seems to be falling apart.

We, of course, know that one of the best sources of mental wellness comes directly from pet ownership. Numerous studies have shown that pet ownership and interactions with pets have direct, tangible benefits on a persons health. But, spreading the word of these benefits has become the watchwords for the Human Animal Bond Research Institute (HABRI).

Founded in 2010 by leaders throughout the pet industry, HABRI works to advance through science, education and advocacy, the vital role of the human-animal bond in the health and well-being of individuals, communities, and companion animals.

In doing so, the organization maintains the worlds largest online library of human-animal bond research, it funds scientific research to document the health benefits of companion animals, and it serves as a liaison to the public for that research.

HABRIs advocacy takes shape in numerous forms, starting with research. To date, HABRI has funded over $3M across 30-plus scientific research projects, demonstrating the health value of companion animals and pets on their owners. Its research partners have included University of Missouri, Tufts University, University of Georgia, and several other major research institutions. In May 2018, HABRI partnered with Mars Petcare to hold a summit on the role of pets in alleviating loneliness, social isolation and other mental ailments; a partnership which continues through this day.

The results of these HABRI-funded research studies have benefitted nearly every walk of life: pets have been shown to improve reading comprehension, reduce classroom disruptions and increase social skill acquisition for third and fourth grade children, have shown improved family function and reduced stress in homes with autistic children, have shown to reduce PTSD symptoms in veterans, and so much more.

HABRIs research partnerships continue to be in the vanguard, showing the benefits of pet ownership and in animal-companionship on the whole. Other research under HABRIs purview has included pet allergy prevention and immunity research, studies into the benefits of companion animals within the workplace, and the correlation between cardiovascular fitness to dog ownership.

Further, HABRIs research has even resulted in changes at the legislative level. The Pet and Women Safety Act, which passed in December 2018, now provides grants to domestic violence shelters to include service animals to aid in rehabilitating victims of domestic violence. Thanks to the tireless advocacy of those in the pet care community, these animals can now help countless individuals across the country.

This comes in conjunction with HABRIs Pet Night on Capitol Hill, a yearly reception in Washington, DC, that provides members of the pet care community to interact with members of Congress, soundly delivering the message that pets are vital for human health and quality of life. While COVID-19 has prevented an in-person Pet Night this year, HABRI was able to shift to Pet Week on Capitol Hill, which featured a full week of programming between legislators and pet care professionals.

And now, in a world that continually faces social isolation and loneliness due to COVID-19-based restrictions, the role of companion animals on our mental health becomes magnified to a powerful degree. HABRI has responded to this need by sharing numerous infographicsavailable on their websitedemonstrating the benefits of pet ownership on longevity, mental health, and more. In addition, HABRI maintains an active social media presence on Facebook, Twitter, Instagram and LinkedIn, sharing up-to-the-minute information on research initiatives, events within the pet care community, and other content that can easily be shared with all those interested in the bond between pets and their owners. Many thanks to Steve Feldman and Lindsey Melfi for contributing valuable content for this article. For those interested in supporting HABRI, viewing the organizations research or downloading HABRI posters, flyers or infographics, visit habri.org.

See the article here:
HABRI Advocates the Human-Animal Bond - Pet Age

Recommendation and review posted by Alexandra Lee Anderson


Page 3«..2345..1020..»